Dr. Novotny is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
600 Moye
Ecu Physicians Pediatrics
Greenville, NC 27834Phone+1 252-744-8279Fax+1 252-744-3829- Is this information wrong?
Education & Training
- Sparrow HospitalResidency, Pediatrics, 1984 - 1985
- St Louis University School of MedicineInternship, Transitional Year, 1981 - 1982
- The University of Toledo College of MedicineClass of 1981
Certifications & Licensure
- NC State Medical License 1993 - 2024
- OH State Medical License 1994 - 1996
- NY State Medical License 1989 - 1994
- MI State Medical License 1984 - 1990
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Critical Care Medicine
Clinical Trials
- The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males Start of enrollment: 2020 Jul 29
- Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies Start of enrollment: 2020 Nov 15
Publications & Presentations
PubMed
- The potential effect of metabolic alkalosis on insulin sensitivity in an adolescent with new‐onset type 1 diabetesWilliam E Novotny, Irma Fiordalisi, Cynthia P Keel, Glenn D. Harris> ;Clinical Case Reports. 2021 May 1
- Why humans should not eat broom straws: Pericarditis and endocarditis.William E Novotny, Cynthia P Keel> ;Annals of Pediatric Cardiology. 2020 May 1
- 43 citationsPhysical Rehabilitation in Critically Ill Children: A Multicenter Point Prevalence Study in the United States.Gertz, S. J., Gertz, S. J., , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,...> ;Critical Care Medicine. 2020 May 1
- Join now to see all
Lectures
- Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-) in Patients with Mantle Cell Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Hospital Affiliations
- ECU Health Medical CenterGreenville, North Carolina
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: